DDDD 4d Pharma Plc

TIDMDDDD

RNS Number : 1516K

4d Pharma PLC

27 August 2019

4D pharma plc

(the "Company" or "4D")

Appointment of independent Non-Executive Director

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Sandy Macrae, PhD, as an independent Non-Executive Director with immediate effect.

Dr. Sandy Macrae has over twenty years of experience in the pharmaceutical industry, with a combination of scientific, medical and commercial expertise. Dr. Macrae currently serves as President and Chief Executive Officer of Sangamo Therapeutics, Inc. ("Sangamo"; NASDAQ: SGMO), a leading genomic medicine company active in developing cell and gene therapies across a range of rare and large indications. Since Dr. Macrae joined Sangamo in 2016, the company has grown to have seven active clinical programmes, established multiple partnerships with major pharma groups, and seen its market capitalisation increase from around $350 million to approximately $1.35 billion today.

Dr. Macrae has previously served as Global Medical Officer of Takeda Pharmaceuticals, overseeing medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences, and knowledge and informatics. Prior to that, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), and Vice President, Business Development. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology.

Duncan Peyton, 4D's Chief Executive Officer, commented: "We welcome Sandy to our Board and very much look forward to working with him at this exciting time in the Company's development. His extensive experience of bringing novel pharmaceuticals to market will be incredibly valuable as we continue to generate the clinical data to bring our products to patients."

The following information is disclosed in accordance with Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

Alexander Donald Macrae, 56, has no current interest in the shares of 4D pharma plc and has the following current and previous company directorships and partnerships:

Current Company Directorships and Partnerships:

Sangamo Therapeutics Inc.

Company Directorships and Partnerships held in last 5 years:

Sangamo Therapeutics UK Limited

Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

 
For further information please contact: 
4D 
 Duncan Peyton, Chief Executive Officer      + 44 (0)113 895 0130 
 N+1 Singer - Nominated Adviser and Joint 
  Broker                                     +44 (0) 20 7496 3000 
 Aubrey Powell/ Justin McKeegan/ Alex Bond 
  (Corporate Finance) 
  Tom Salvesen (Corporate Broking) 
 Bryan Garnier & Co. Limited - Joint Broker  +44 (0)20 7332 2500 
 Dominic Wilson /Phil Walker 
 
  About 4D 
 
Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, 
 a novel and emerging class of drugs, defined by the FDA as biological products that contain 
 a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure 
 of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies 
 Live Biotherapeutics based on a deep understanding of function and mechanism. 4D's Live Biotherapeutic 
 products are orally delivered single strains of bacteria that are naturally found in the healthy 
 human gut. The Company has four clinical studies in progress, namely a Phase II clinical study 
 of Blautix in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with 
 KEYTRUDA(R) (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant 
 setting for patients with solid tumours and a Phase I/II study of MRx-4DP0004 in asthma. Other 
 focus programmes include disease areas such as CNS disease. 
 
 

About 4D

For more information, refer to https://www.4dpharmaplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAUNRBRKBAWUAR

(END) Dow Jones Newswires

August 27, 2019 02:02 ET (06:02 GMT)

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Apr 2023 a Apr 2024